[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C@H1][C][N][Branch2][Branch1][O][C][C][N][Ring1][=Branch1][C][=N][C][=Branch1][C][=O][N][Branch2][Ring1][N][C][=N][C][=Branch1][O][=C][Branch1][#Branch1][C][=C][Ring1][=Branch1][Ring1][O][F][C][=C][Branch1][Branch2][C][=C][C][=C][Ring1][=Branch1][F][O][C][=C][Branch1][N][C][=C][N][=C][Ring1][=Branch1][C][Branch1][C][C][C][C][C][=Branch1][C][=O][C][=C]"}, {"from": "gpt", "value": "The molecule is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS mutations. Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s. It is the first experimental KRAS inhibitor. The drug [MRTX849] is also currently being developed and has the same target.  Sotorasib was granted FDA approval on May 28, 2021, followed by the European Commission's approval on January 10, 2022."}]